Exchange: NASDAQ·Updated 12:18 PM EDT

INDV News

News
all
press releases
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Why Indivior Pharmaceuticals Inc. (INDV) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Indivior Pharmaceuticals Inc. (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages...
Business Wire
3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.
Zacks
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
Zacks
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.
Zacks
Here's Why Indivior Pharmaceuticals Inc. (INDV) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"
Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.
Zacks
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction...
Business Wire

Advertisement|Remove ads.